Page last updated: 2024-09-05

zm 241385 and Hepatic Encephalopathy

zm 241385 has been researched along with Hepatic Encephalopathy in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ackerman, Z; Avraham, Y; Berry, EM; Magen, I; Mechoulam, R; Vorobiev, L	1

Other Studies

1 other study(ies) available for zm 241385 and Hepatic Encephalopathy

Article	Year
Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. Journal of hepatology, 2009, Volume: 51, Issue:3 Topics: Adenosine A2 Receptor Antagonists; Animals; Bile Ducts; Brain-Derived Neurotrophic Factor; Cannabidiol; Chronic Disease; Cognition; Cognition Disorders; Cyclooxygenase 2; Disease Models, Animal; Female; Gait Disorders, Neurologic; Hepatic Encephalopathy; Ligation; Liver Diseases; Mice; Mice, Inbred Strains; Motor Activity; Receptor, Adenosine A2A; Receptors, Tumor Necrosis Factor, Type I; RNA, Messenger; Treatment Outcome; Triazines; Triazoles	2009

Article

Year

Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation.

Journal of hepatology, 2009, Volume: 51, Issue:3

Topics: Adenosine A2 Receptor Antagonists; Animals; Bile Ducts; Brain-Derived Neurotrophic Factor; Cannabidiol; Chronic Disease; Cognition; Cognition Disorders; Cyclooxygenase 2; Disease Models, Animal; Female; Gait Disorders, Neurologic; Hepatic Encephalopathy; Ligation; Liver Diseases; Mice; Mice, Inbred Strains; Motor Activity; Receptor, Adenosine A2A; Receptors, Tumor Necrosis Factor, Type I; RNA, Messenger; Treatment Outcome; Triazines; Triazoles

2009